RADAR-AD
Research type
Research Study
Full title
Remote Assessment of Disease And Relapse - Alzheimer’s Disease
IRAS ID
269516
Contact name
Dag Aarsland
Contact email
Sponsor organisation
King's College London
Clinicaltrials.gov Identifier
20/LO/0183, 20/LO/0183
Duration of Study in the UK
2 years, 5 months, 25 days
Research summary
Alzheimer’s Disease (AD) is associated with staggering costs and suffering, particularly the social impact of caring for increasingly disabled individuals. These functional disabilities can be almost undetectable in the early stages of the disease, worsening over time, often at varying rates of progression. The measurement of such functional disabilities is typically insensitive and relies on direct observation or caregiver recall. Digital technologies, particularly those based on the use of smartphones, wearables and/or home-based monitoring devices - here defined as ‘Remote Measurement Technologies’ (RMTs) - provide an opportunity to change radically the way in which functional assessment is undertaken in AD. RMTs have the potential to obtain better measurements of behavioural and biological parameters associated with individual Activities of Daily Living (ADL), when compared to the current subjective scales or questionnaires. Divergence from normative ADL profiles could objectively indicate the presence of specific functional disabilities even at the very early stages of AD. Therefore, the main hypothesis of this multicentre digital assessment study lasting 8 weeks is that RMTs should allow the detection of impairments in functional component of ADLs that occur below the threshold of clinical scale detection or disability questionnaires that are routinely used in dementia clinics. The primary objective of this study is to assess the performance of selected RMTs against standardised rating scales of ADLs in subjects with mild-to-moderate AD. Secondary objectives are, (a) to evaluate associations between RMTs and standard clinical scales used to characterise people with AD diagnosis, (b) to investigate the patient acceptability of selected RMTs used for the duration of the study, and (c) to assess the technical performance of RMTs and digital platform in a real-life setting.
REC name
London - West London & GTAC Research Ethics Committee
REC reference
20/LO/0183
Date of REC Opinion
30 Apr 2020
REC opinion
Further Information Favourable Opinion